Status:

SUSPENDED

Physician-modified Endovascular Graft for Repair of Complex Thoracoabdominal and Abdominal Aortic Aneurysms

Lead Sponsor:

Medstar Health Research Institute

Conditions:

Juxtarenal Aortic Aneurysm

Suprarenal Aortic Aneurysm

Eligibility:

All Genders

18+ years

Phase:

NA

Brief Summary

The primary objective of this study is to assess the use of a physician-modified Cook Alpha Thoracic Endovascular Graft in the repair of complex aortic aneurysms and thoracoabdominal aortic aneurysms ...

Detailed Description

This study is a prospective, single-center, non-randomized, single-arm study. Each enrolled subject will undergo periodic follow-up evaluations involving physical exams, computed tomography angiograph...

Eligibility Criteria

Inclusion

  • Age ≥ 18 years old
  • Life expectancy \> 2 year(s)
  • Patient is considered to be at high risk of morbidity and mortality with open surgical repair
  • A patient may be entered into the study if the patient has at least one of the following:
  • Juxtarenal, suprarenal or a thoracoabdominal aortic aneurysm with a diameter ≥ 5.5 cm or 2 times the normal aortic diameter
  • Aneurysm with a history of growth ≥ 0.5 cm per year
  • Saccular aneurysms deemed at significant risk for rupture based upon physician interpretation
  • Symptomatic juxtarenal, suprarenal or a thoracoabdominal aortic aneurysm
  • Thoracoabdominal aortic aneurysms secondary to aortic dissection meeting above criteria
  • Patient is considered to be at high risk of morbidity and mortality with open surgical repair
  • Iliac or femoral access vessel morphology that is compatible with vascular access techniques, devices or accessories, with or without use of a surgical conduit
  • Nonaneurysmal aortic segment proximal to the aneurysm (neck) with a:
  • Minimum neck length of 20mm
  • Diameter in the range of 21-38mm
  • Angle less than 60° relative to the axis of the aneurysm
  • Angle less than 60° relative to the axis of the suprarenal aorta
  • Minimum branch vessel diameter greater than 5 mm
  • Iliac artery distal fixation site greater than 10mm in length and diameter in the range of 8-21mm.

Exclusion

  • Under the age of 18 years
  • Can be treated in accordance with the instructions for use with a legally marketed endovascular prosthesis
  • Is eligible for enrollment in a manufacturer-sponsored IDE at the investigational site
  • Willing to participate in a sponsor-investigator IDE with access to a non-physician modified endovascular prostheses at the investigational site
  • Willing to travel to an investigational site with access to a non-physician modified endovascular prosthesis
  • Unwilling or unable to comply with the follow-up schedule
  • Inability or refusal to give informed consent by patient or legal representative
  • Patient is pregnant or breastfeeding
  • Life expectancy \< 2-years despite successful aneurysm exclusion
  • Free rupture with hemodynamic instability
  • Ongoing infection
  • Diagnosis of, or suspected connective tissue disease
  • Known sensitivities or allergies to the materials of construction of the devices
  • Known hypersensitivity or contraindication to anticoagulation or contrast media that cannot be adequately medically managed
  • Uncorrectable coagulopathy
  • Body habitus that would inhibit x-ray visualization of the aorta or exceeds the safe capacity of the equipment
  • Patient has had a major surgical or interventional procedure unrelated to the treatment of the aneurysm planned ≤ 30 days of the endovascular repair
  • Unstable angina (defined as angina with a progressive increase in symptoms, new onset at rest or nocturnal angina)
  • Systemic or local infection that may increase the risk of endovascular graft infection
  • Leaking or free rupture of aneurysm associated with hemodynamic instability.
  • Baseline creatinine greater than 3.0 mg/dL
  • Known history of, or suspected connective tissue disorders (e.g., Marfan Syndrome, Ehler's Danlos Syndrome)
  • Anatomical exclusion criteria:
  • Inadequate femoral or iliac access compatible with the required delivery systems, not amenable to open surgical or endovascular conduit placement
  • Absence of a non-aneurysmal aortic segment for proximal seal zone with:
  • A diameter measured outer wall to outer wall of no greater than 38mm and no less than 21 mm;
  • Parallel aortic wall with \<20% diameter change and without significant calcification and/or thrombus in the selected area of seal zone
  • Visceral vessel anatomy not compatible with physician-modified Zenith® Alpha Endovascular Graft due to excessive occlusive disease or small size not amenable to stent graft placement
  • Unsuitable distal iliac artery fixation site and anatomy:
  • Common iliac artery fixation site diameter measured outer wall to outer wall on a sectional image (CT) \<8.0 mm with inability to perform open surgical conduit
  • Iliac artery diameter measured outer wall to outer wall on a sectional image (CT) \>21 mm at distal fixation site, with inability to perform open internal iliac artery revascularization or iliac branch stent graft
  • Iliac artery distal fixation site \<10 mm in length
  • Inability to preserve at least one hypogastric artery

Key Trial Info

Start Date :

September 20 2021

Trial Type :

INTERVENTIONAL

Allocation :

ESTIMATED

End Date :

September 1 2028

Estimated Enrollment :

200 Patients enrolled

Trial Details

Trial ID

NCT04526938

Start Date

September 20 2021

End Date

September 1 2028

Last Update

August 29 2025

Active Locations (1)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 1 (1 locations)

1

MedStar Washington Hospital Center

Washington D.C., District of Columbia, United States, 20010